Review: The New Concept of ‘‘Interventional Heart Failure Therapy’’: Part 2—Inotropes, Valvular Disease, Pumps, and Transplantation

Recent advances in heart failure therapy include a variety of mechanical and device-based technologies that target structural aspects of heart failure that cannot be treated with drug therapy alone; these newer therapies can collectively be described as interventional heart failure therapy. This article is the second in a 2-part series reviewing interventional heart failure therapy. Interventions included in this discussion include those indicated for the treatment of end-stage refractory heart failure, including interventional medical therapy, interventional treatment of valvular disease, mechanical assist devices, and heart transplantation. Also included is a review of the currently available catheter-based pumps, which are intended to provide temporary support in patients with acute hemodynamic compromise. The use of cellular or stem cell therapy for the treatment of heart failure is an emerging interventional therapy and data supporting its use for the treatment heart failure will also be presented, as will a discussion of the role of palliative care and self-care in heart failure therapy.

[1]  M. Cheitlin Adult Bone Marrow–Derived Cells for Cardiac Repair: A Systematic Review and Meta-analysis , 2008 .

[2]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2009, Circulation.

[3]  N. Smedira,et al.  Mechanical Unloading Restores &bgr;-Adrenergic Responsiveness and Reverses Receptor Downregulation in the Failing Human Heart , 2001, Circulation.

[4]  M. Sebern,et al.  Psychometric testing of the self-care of heart failure index. , 2004, Journal of cardiac failure.

[5]  S. Houser,et al.  Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. , 1998, Circulation.

[6]  W J KOLFF,et al.  Diastolic balloon pumping (with carbon dioxide) in the aorta--a mechanical assistance to the failing circulation. , 1962, American heart journal.

[7]  S. Ayres,et al.  The effects of intra-aortic counterpulsation on cardiac performance and metabolism in shock associated with acute myocardial infarction. , 1971, The Journal of clinical investigation.

[8]  R. Schlant,et al.  A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. , 1989, The New England journal of medicine.

[9]  R. Körfer,et al.  Single-center experience with the thoratec ventricular assist device. , 2000, The Journal of thoracic and cardiovascular surgery.

[10]  D. Burkhoff,et al.  Chronic Unloading by Left Ventricular Assist Device Reverses Contractile Dysfunction and Alters Gene Expression in End-Stage Heart Failure , 2000, Circulation.

[11]  W. Koch,et al.  Differential gene expression and genomic patient stratification following left ventricular assist device support. , 2003, Journal of the American College of Cardiology.

[12]  T. Marwick,et al.  Effect of Aldosterone Antagonism on Myocardial Dysfunction in Hypertensive Patients With Diastolic Heart Failure , 2004, Circulation.

[13]  M. Al-mallah,et al.  Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. , 2007, Archives of internal medicine.

[14]  F. Pagani,et al.  Left ventricular assist device therapy improves utilization of donor hearts. , 2002, Journal of the American College of Cardiology.

[15]  R. Bolli,et al.  Adult bone marrow–derived cells: Regenerative potential, plasticity, and tissue commitment , 2005, Basic Research in Cardiology.

[16]  M C Oz,et al.  Long-term use of a left ventricular assist device for end-stage heart failure. , 2001, The New England journal of medicine.

[17]  M. Yacoub,et al.  Changes in sarcolemmal Ca entry and sarcoplasmic reticulum Ca content in ventricular myocytes from patients with end-stage heart failure following myocardial recovery after combined pharmacological and ventricular assist device therapy. , 2003, European heart journal.

[18]  Patrick W Serruys,et al.  Catheter-based intramyocardial injection of autologous skeletal myoblasts as a primary treatment of ischemic heart failure: clinical experience with six-month follow-up. , 2003, Journal of the American College of Cardiology.

[19]  M. Slaughter,et al.  Results of a multicenter clinical trial with the Thoratec Implantable Ventricular Assist Device. , 2007, The Journal of thoracic and cardiovascular surgery.

[20]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2010 update: a report from the American Heart Association. , 2010, Circulation.

[21]  Eric I. Rossman,et al.  Altered myocardial Ca2+ cycling after left ventricular assist device support in the failing human heart. , 2004, Journal of the American College of Cardiology.

[22]  E. Ohman,et al.  The current practice of intra-aortic balloon counterpulsation: results from the Benchmark Registry. , 2001, Journal of the American College of Cardiology.

[23]  M. Jessup,et al.  A prospective study of continuous intravenous milrinone therapy for status IB patients awaiting heart transplant at home. , 2004, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[24]  Peter W. Laird,et al.  Rebuilding a Damaged Heart: Long-Term Survival of Transplanted Neonatal Rat Cardiomyocytes After Myocardial Infarction and Effect on Cardiac Function , 2002, Circulation.

[25]  Daniel Burkhoff,et al.  Mechanical Device–Based Methods of Managing and Treating Heart Failure , 2005, Circulation.

[26]  K. Furie,et al.  Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2007, Circulation.

[27]  O H Frazier,et al.  Use of a continuous-flow device in patients awaiting heart transplantation. , 2007, The New England journal of medicine.

[28]  M. Gheorghiade,et al.  Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. , 2007, American heart journal.

[29]  O. Alfieri,et al.  The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) Trial: First Randomized Placebo-Controlled Study of Myoblast Transplantation , 2008, Circulation.

[30]  C. Nienaber,et al.  Transcatheter Transplantation of Autologous Skeletal Myoblasts in Postinfarction Patients with Severe Left Ventricular Dysfunction , 2004, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[31]  E. Marbán,et al.  Regenerative Potential of Cardiosphere-Derived Cells Expanded From Percutaneous Endomyocardial Biopsy Specimens , 2007, Circulation.

[32]  Jg Copeland,et al.  CardioWest Total Artificial Heart Investigators. Cardiac replacement with a total artificial heart as a bridge to transplantation , 2004 .

[33]  G. Guyatt,et al.  A controlled trial of digoxin in congestive heart failure. , 1988, The American journal of cardiology.

[34]  R. Kloner,et al.  Cellular cardiomyoplasty--cardiomyocytes, skeletal myoblasts, or stem cells for regenerating myocardium and treatment of heart failure? , 2003, Cardiovascular research.

[35]  D. Burkhoff,et al.  A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. , 2006, American heart journal.

[36]  L. Appel,et al.  State of the science: promoting self-care in persons with heart failure: a scientific statement from the American Heart Association. , 2009, Circulation.

[37]  Kathryn H. Dansky,et al.  Impact of Telehealth on Clinical Outcomes in Patients With Heart Failure , 2008, Clinical nursing research.

[38]  P. Herijgers,et al.  Initial experiences with the Impella device in patients with cardiogenic shock - Impella support for cardiogenic shock. , 2003, The Thoracic and cardiovascular surgeon.

[39]  R. Dobbs,et al.  Maintenance digoxin after an episode of heart failure: placebo-controlled trial in outpatients. , 1977, British medical journal.

[40]  R. A. Johnson,et al.  Heart failure in outpatients: a randomized trial of digoxin versus placebo. , 1982, The New England journal of medicine.

[41]  J. Holtz,et al.  Myocardial gene expression of regulators of myocyte apoptosis and myocyte calcium homeostasis during hemodynamic unloading by ventricular assist devices in patients with end-stage heart failure. , 1999, Circulation.

[42]  G. Schuler,et al.  Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. , 2003, European heart journal.

[43]  P. Menasché Stem cell therapy for heart failure: are arrhythmias a real safety concern? , 2009, Circulation.

[44]  G. Noon,et al.  Regression of fibrosis and hypertrophy in failing myocardium following mechanical circulatory support. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[45]  Heather Sherrard,et al.  Telehome monitoring in patients with cardiac disease who are at high risk of readmission. , 2008, Heart & lung : the journal of critical care.

[46]  S. Mallon,et al.  Long-term (> 8 weeks) home inotropic therapy as destination therapy in patients with advanced heart failure or as bridge to heart transplantation. , 2005, International journal of cardiology.

[47]  S. Houser,et al.  Regression of cellular hypertrophy after left ventricular assist device support. , 1998, Circulation.

[48]  C. Weber,et al.  Transplantation of fetal cardiomyocytes into infarcted rat hearts results in long-term functional improvement. , 2004, Tissue engineering.

[49]  Nader Moazami,et al.  Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. , 2009, Journal of the American College of Cardiology.

[50]  A. Feldman,et al.  Downregulation of Matrix Metalloproteinases and Reduction in Collagen Damage in the Failing Human Heart After Support With Left Ventricular Assist Devices , 2001, Circulation.

[51]  K. Naunheim,et al.  Clinical experience with 111 thoratec ventricular assist devices. , 1999, The Annals of thoracic surgery.

[52]  R. Califf,et al.  Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). , 1999, American heart journal.

[53]  Sarah J. Goodlin,et al.  Palliative care in congestive heart failure. , 2009, Journal of the American College of Cardiology.

[54]  M. Zile,et al.  Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. , 2008, Journal of the American College of Cardiology.

[55]  R. Bolman,et al.  Effects of left ventricular assist devices on outcomes in patients undergoing heart transplantation. , 2000, The Annals of thoracic surgery.

[56]  E. Marbán,et al.  Stem cells in the heart: what's the buzz all about?--Part 1: preclinical considerations. , 2008, Heart rhythm.

[57]  William T. Abraham,et al.  Focused Update : ACCF / AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults , 2013 .

[58]  S. Katz,et al.  Home continuous positive inotropic infusion as a bridge to cardiac transplantation in patients with end-stage heart failure. , 2004, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[59]  F. Oliva,et al.  Monitoring Intrathoracic Impedance with an Implantable Defibrillator Reduces Hospitalizations in Patients with Heart Failure , 2009, Pacing and clinical electrophysiology : PACE.

[60]  M. Cheitlin,et al.  The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) Trial: First Randomized Placebo-Controlled Study of Myoblast Transplantation , 2009 .

[61]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2009, Circulation.

[62]  S. Russell,et al.  Advanced heart failure treated with continuous-flow left ventricular assist device. , 2009, The New England journal of medicine.

[63]  C. Lau,et al.  Intrathoracic Impedance Monitoring in Patients With Heart Failure: Correlation With Fluid Status and Feasibility of Early Warning Preceding Hospitalization , 2005, Circulation.

[64]  A. Hatzopoulos,et al.  Stem cell therapy for cardiac repair: benefits and barriers , 2009, Expert Reviews in Molecular Medicine.

[65]  G. Lamas,et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.

[66]  Adnan Kastrati,et al.  A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. , 2008, Journal of the American College of Cardiology.

[67]  B. Marić,et al.  A systematic review of telemonitoring technologies in heart failure , 2009, European Journal of Heart Failure.

[68]  A. Khaghani,et al.  Clinical Recovery From End-Stage Heart Failure Using Left-Ventricular Assist Device and Pharmacological Therapy Correlates With Increased Sarcoplasmic Reticulum Calcium Content but Not With Regression of Cellular Hypertrophy , 2004, Circulation.

[69]  D. Burkhoff,et al.  Comparison of Right and Left Ventricular Responses to Left Ventricular Assist Device Support in Patients With Severe Heart Failure: A Primary Role of Mechanical Unloading Underlying Reverse Remodeling , 2001, Circulation.

[70]  A. Hagège,et al.  Does transplantation of cardiomyocytes improve function of infarcted myocardium? , 1997, Circulation.